Eli Lilly Diabetes Drug Franchise Remains Strong, Analyst Praises Foundayo Trajectory
Guggenheim raises PT to $1,284, citing strong tirzepatide and improving Foundayo trends; estimates exceed consensus.
Share
Why It Matters
An expert thinks Eli Lilly's diabetes medicines are selling really well. This suggests the company is doing what it promised to do.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.